Consistent Patterns in the Development and Immunodominance of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ T-Cell Responses following Acute HIV-1 Infection

ABSTRACT Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses generated during acute infection play a critical role in the initial control of viremia. However, little is known about the viral T-cell epitopes targeted during acute infection or about their hierarchy in appearance and relative immunodominance over time. In this study, HIV-1-specific CD8+ T-cell responses in 18 acutely infected individuals expressing HLA-A3 and/or -B7 were characterized. Detailed analysis of CD8 responses in one such person who underwent treatment of acute infection followed by reexposure to HIV-1 through supervised treatment interruptions (STI) revealed recognition of only two cytotoxic T-lymphocyte (CTL) epitopes during symptomatic acute infection. HIV-1-specific CD8+ T-cell responses broadened significantly during subsequent exposure to the virus, ultimately targeting 27 distinct CTL epitopes, including 15 different CTL epitopes restricted by a single HLA class I allele (HLA-A3). The same few peptides were consistently targeted in an additional 17 persons expressing HLA-A3 and/or -B7 during acute infection. These studies demonstrate a consistent pattern in the development of epitope-specific responses restricted by a single HLA allele during acute HIV-1 infection, as well as persistence of the initial pattern of immunodominance during subsequent STI. In addition, they demonstrate that HIV-1-specific CD8+ T-cell responses can ultimately target a previously unexpected and unprecedented number of epitopes in a single infected individual, even though these are not detectable during the initial exposure to virus. These studies have important implications for vaccine design and evaluation.

[1]  B. Walker,et al.  HLA-B57-Restricted Cytotoxic T-Lymphocyte Activity in a Single Infected Subject toward Two Optimal Epitopes, One of Which Is Entirely Contained within the Other , 2000, Journal of Virology.

[2]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[3]  M. Altfeld,et al.  The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. , 2000, Current opinion in immunology.

[4]  Stephen P. Schoenberger,et al.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.

[5]  E. Rosenberg,et al.  Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection , 2001, The Journal of experimental medicine.

[6]  G. M. Ortiz,et al.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[7]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.

[8]  B. Walker,et al.  Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. , 1998, Journal of immunology.

[9]  B. Walker,et al.  Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition , 1997, Journal of virology.

[10]  Susan M. Kaech,et al.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.

[11]  D. Montefiori,et al.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Eric G. Pamer,et al.  Early Programming of T Cell Populations Responding to Bacterial Infection1 , 2000, The Journal of Immunology.

[13]  E. Rosenberg,et al.  Identification of Dominant Optimal HLA-B60- and HLA-B61-Restricted Cytotoxic T-Lymphocyte (CTL) Epitopes: Rapid Characterization of CTL Responses by Enzyme-Linked Immunospot Assay , 2000, Journal of Virology.

[14]  E. Rosenberg,et al.  Vpr Is Preferentially Targeted by CTL During HIV-1 Infection1 , 2001, The Journal of Immunology.

[15]  R. Young,et al.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Blattner,et al.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. , 1997, The Journal of clinical investigation.

[17]  Steven M. Wolinsky,et al.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes , 2002, Nature.

[18]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[19]  R. Kaul,et al.  New Insights into Host Factors in HIV-1 Pathogenesis , 2001, Cell.

[20]  J. Kilby,et al.  Perspectives on inducing efficient immune control of HIV-1 replication - a new goal for HIV therapeutics? , 2001, AIDS (London).

[21]  J. Sidney,et al.  HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.

[22]  S. Rowland-Jones,et al.  Cellular immune responses to HIV , 2001, Nature.

[23]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[24]  E. Rosenberg,et al.  Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chronic HIV Infection , 2001, The Journal of experimental medicine.

[25]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[26]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[27]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[28]  V. Appay,et al.  Memory CD8+ T cells in HIV infection. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[29]  Martin A. Nowak,et al.  Antigenic oscillations and shifting immunodominance in HIV-1 infections , 1995, Nature.

[30]  M. Altfeld,et al.  Less is more? STI in acute and chronic HIV-1 infection , 2001, Nature Medicine.

[31]  Alessandro Sette,et al.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.

[32]  B. Walker,et al.  Anti-HIV cellular immunity: recent advances towards vaccine design. , 1999, AIDS.

[33]  Bucy Rp,et al.  Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics? , 2001 .

[34]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[35]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[36]  Todd M. Allen,et al.  CD8+ Lymphocytes from Simian Immunodeficiency Virus-Infected Rhesus Macaques Recognize 14 Different Epitopes Bound by the Major Histocompatibility Complex Class I Molecule Mamu-A*01: Implications for Vaccine Design and Testing , 2001, Journal of Virology.

[37]  A. Hughes,et al.  Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. , 1991, Journal of immunology.

[38]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[39]  A. Oxenius,et al.  Cytotoxic T Lymphocyte Responses to Human Immunodeficiency Virus: Control and Escape , 2000, Stem cells.

[40]  R. Paredes,et al.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[41]  E. Rosenberg,et al.  Functionally Inert HIV-Specific Cytotoxic T Lymphocytes Do Not Play a Major Role in Chronically Infected Adults and Children , 2000, The Journal of experimental medicine.

[42]  B. Walker,et al.  Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. , 1997, Journal of immunology.

[43]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[44]  E. Rosenberg,et al.  Rapid Definition of Five Novel HLA-A∗3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays , 2001, Journal of Virology.

[45]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[46]  A. Trkola,et al.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.

[47]  M. Bunce,et al.  Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.

[48]  R. Siliciano,et al.  Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env. , 1998, AIDS research and human retroviruses.